A detailed history of Price T Rowe Associates Inc transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,036,911 shares of ZNTL stock, worth $3.31 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,036,911
Previous 923,901 12.23%
Holding current value
$3.31 Million
Previous $3.78 Million 0.98%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.9 - $4.57 $327,729 - $516,455
113,010 Added 12.23%
1,036,911 $3.82 Million
Q2 2024

Aug 14, 2024

SELL
$4.09 - $16.13 $10.5 Million - $41.4 Million
-2,565,808 Reduced 73.52%
923,901 $3.78 Million
Q1 2024

May 15, 2024

BUY
$10.83 - $16.49 $6.34 Million - $9.66 Million
585,644 Added 20.17%
3,489,709 $55 Million
Q4 2023

Feb 14, 2024

BUY
$9.84 - $20.13 $1.85 Million - $3.79 Million
188,466 Added 6.94%
2,904,065 $44 Million
Q3 2023

Nov 14, 2023

BUY
$19.63 - $28.29 $613,378 - $883,977
31,247 Added 1.16%
2,715,599 $54.5 Million
Q2 2023

Aug 14, 2023

BUY
$17.41 - $30.05 $8.43 Million - $14.5 Million
484,183 Added 22.01%
2,684,352 $75.7 Million
Q1 2023

May 15, 2023

BUY
$16.14 - $24.94 $378,789 - $585,316
23,469 Added 1.08%
2,200,169 $37.8 Million
Q4 2022

Feb 14, 2023

SELL
$18.07 - $25.6 $741,592 - $1.05 Million
-41,040 Reduced 1.85%
2,176,700 $43.8 Million
Q3 2022

Nov 14, 2022

SELL
$20.23 - $31.73 $42.1 Million - $66 Million
-2,080,811 Reduced 48.41%
2,217,740 $48 Million
Q2 2022

Aug 15, 2022

BUY
$17.91 - $52.25 $1.8 Million - $5.24 Million
100,371 Added 2.39%
4,298,551 $121 Million
Q1 2022

May 16, 2022

SELL
$41.58 - $80.89 $7.68 Million - $14.9 Million
-184,701 Reduced 4.21%
4,198,180 $194 Million
Q4 2021

Feb 14, 2022

BUY
$66.92 - $84.79 $43.7 Million - $55.3 Million
652,456 Added 17.49%
4,382,881 $368 Million
Q3 2021

Nov 15, 2021

BUY
$46.83 - $73.5 $22.1 Million - $34.6 Million
470,857 Added 14.45%
3,730,425 $249 Million
Q2 2021

Aug 16, 2021

BUY
$37.41 - $62.25 $81.4 Million - $135 Million
2,175,322 Added 200.63%
3,259,568 $173 Million
Q1 2021

May 17, 2021

SELL
$35.69 - $52.72 $349,048 - $515,601
-9,780 Reduced 0.89%
1,084,246 $47 Million
Q4 2020

Feb 16, 2021

BUY
$31.71 - $57.97 $34.7 Million - $63.4 Million
1,094,026 New
1,094,026 $56.8 Million

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $182M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.